A multi-center clinical trial of Qianlieantong tablets for chronic prostatitis.
- Author:
Kai GUO
1
;
Ming-Xing QIU
;
Song-Liang CAI
;
Jing LENG
;
Yin-Fa HAN
;
Guo-Xing SHAO
;
Chuan-Hang WANG
;
Xiang-An TU
;
Luo-Yan YANG
;
Ge-Ming CHEN
;
Qiang ZHOU
;
Yong DENG
;
Xiao-Long WANG
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Chronic Disease; Drug Administration Schedule; Drugs, Chinese Herbal; administration & dosage; therapeutic use; Humans; Male; Medicine, Chinese Traditional; Middle Aged; Prostatitis; drug therapy; Quality of Life; Tablets; Treatment Outcome
- From: National Journal of Andrology 2007;13(10):950-952
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the efficacy and safety of Qianlieantong Tablets in the treatment of chronic prostatitis.
METHODSA multi-center, self-controlled open clinical trial was conducted. A total of 280 subjects with chronic prostatitis were enrolled and treated by Qianlieantong Tablets, 3 times a day, 5 tablets each time. Before and after 2 and 4 weeks after the administration, NIH-CPSI scores and white blood cell counts in the prostate secretion were recorded.
RESULTSOf the 273 subjects evaluated, the rates of excellence, effectiveness and ineffectiveness were 35.2% (n = 96), 47.6% (n = 130) and 17.2% (n = 47), respectively, with a total effectiveness rate of 82.8%. After 4 weeks'medication, the scores of the subjects on NIH-CPSI pain, voiding and quality of life and white blood cell counts in prostate secretion were significantly decreased compared with pre-treatment (P < 0.01). No adverse events or laboratory abnormality related to the medication were observed.
CONCLUSIONQianlieantong Tablets has a significant effect on chronic prostatitis with high safety, particularly indicated in chronic prostatitis with pelvic pain.
